Accueil › Lymphome de Burkitt › Ohio
Essais cliniques pour Lymphome de Burkitt dans Ohio
17 études pour Lymphome de Burkitt recherchent des participants dans Ohio.
Villes dans Ohio
Texte officiel de l'étude (anglais)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- et 3 autres
Recrutement en coursPhase 2
366 Days – 46 Years · Tous sexes · Mis à jour le 2 oct. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Case Western Reserve University, Cleveland
- Cleveland Clinic Foundation, Cleveland
- et 2 autres
Recrutement en coursPhase 3
Âges de 18 à 39 · Tous sexes · Mis à jour le 2 oct. 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
Recrutement en coursÉtude observationnelle
Âges de 0 à 38 · Tous sexes · Mis à jour le 1 oct. 2026 · NCT06131801Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- et 2 autres
Recrutement en coursPhase 2
365 Days · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 21 sept. 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
Recrutement en coursPhase 3
Âges de 1 ans et plus · Tous sexes · Mis à jour le 17 sept. 2026 · NCT07223021A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- et 3 autres
Recrutement en coursPhase 2
Âges de 1 à 30 · Tous sexes · Mis à jour le 1 sept. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- et 4 autres
Recrutement en coursPhase 3
365 Days – 25 Years · Tous sexes · Mis à jour le 25 août 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
Recrutement en coursPhase 2
Âges de 7 à 25 · Tous sexes · Mis à jour le 19 août 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
Recrutement en coursPhase 1/2
Âges de 13 à 90 · Tous sexes · Mis à jour le 6 août 2026 · NCT06533579Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Recrutement en coursPhase 1
Âges de 2 ans et plus · Tous sexes · Mis à jour le 29 mai 2026 · NCT05418088Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Cleveland Clinic Foundation, Cleveland
Recrutement en coursPhase 2
Âges de 18 à 54 · Tous sexes · Mis à jour le 17 mars 2026 · NCT06918431Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
Recrutement en coursPhase 1
Âges de 1 à 39 · Tous sexes · Mis à jour le 18 févr. 2026 · NCT06863259Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 13 févr. 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Cleveland Clinic, Cleveland
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 5 nov. 2025 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 15 nov. 2024 · NCT06034275Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.